Hims and Hers Health Inc vs T1 Energy Inc. Common Stock — how do they compare? Hims and Hers Health Inc trades at $27.29 (market cap $6.47B), while T1 Energy Inc. Common Stock trades at $2.76 (market cap $946.42M). The key difference: Hims and Hers Health Inc is far larger — about 6.8× T1 Energy Inc. Common Stock's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, T1 Energy Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| HIMS | TE | |
|---|---|---|
Market Cap | $6.47B | $946.42M |
Volume | 10,989,212 | 12,898,774 |
Sector | Health | Industrials |
52-Week High | $62.76 | $12.04 |
52-Week Low | $14.52 | $2.72 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $7.17B | $1.72B |
Signals from Pluang's Aura AI — not financial advice
HIMS trades at $29.71, down 3.04% today, amid ongoing securities class action lawsuits. The stock shows bullish technical signals with strong moving average support and key resistance at $32. Fundamentally, while revenue grew to $2.35B in 2025, the company posted a net loss of -$142M in 2026 with negative profit margins, though it maintains a solid gross margin of 68.4%.
The investment outlook is mixed: technical indicators suggest near-term upside potential toward the $32.17 consensus target, but fundamental weakness and legal overhangs pose significant risks. Analyst sentiment leans cautious with 65% hold ratings, reflecting concerns about profitability and regulatory challenges despite growth prospects.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →